Blueprint Still Confident In CDK2 Inhibitor Despite Partial Hold On Phase I/II Trial

 
• By Alaric DeArment
  
Blueprint said the FDA placed a partial hold on its Phase I/II CDK2 inhibitor trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D